OTC Products · LP-221
Ibuprofen Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-221OTC Products
- Generic identity
- IbuprofenTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-221
- Generic identity
- Ibuprofen
- Presentation
- Tablet
- Catalogue strength
- 200 mg; 400 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: ibuprofen.
- Dosage form: tablet.
- Proposed strengths: 200 mg and 400 mg.
- General proposed pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Strength-to-pack/SKU mapping.
- Tablet coating, score/divisibility and release characteristics.
- Approved indication, age range, dosing and warnings.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg | Tablet | — | General blister 10 × 10 tablets; strength mapping not supplied | No release/divisibility or approved-use inference from strength alone. |
| B | 400 mg | Tablet | — | General blister 10 × 10 tablets; strength mapping not supplied | No release/divisibility or approved-use inference from strength alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ibuprofen is a non-steroidal anti-inflammatory drug used for selected pain, fever and inflammatory symptoms. It reduces prostaglandin production and has effects beyond symptom relief, including on the stomach and kidneys. The oral tablet form is distinct from paediatric suspensions and topical products. Its availability without prescription in some markets does not establish unrestricted suitability or the legal category of this candidate.
Clinical context and therapeutic role
Clinical or pharmacy assessment considers the cause and duration of symptoms, hydration, age, comorbidity and other medicines. Persistent fever or pain can require investigation rather than repeated symptom suppression. Ibuprofen should not be casually combined with other NSAIDs, and combination cold or pain products can duplicate exposure. This educational page does not provide a regimen, paediatric conversion or candidate-specific list of approved uses.
Selected safety context
Gastrointestinal bleeding, ulceration, kidney injury and fluid retention are important concerns. NSAID-related asthma, severe allergy and skin reactions can occur, and cardiovascular risk depends on the patient and exposure. Dehydration, kidney disease, previous gastrointestinal bleeding and interacting anticoagulants or renal medicines require review. Pregnancy-related restrictions need current medical guidance. Vomiting blood, black stools, severe breathing difficulty or reduced urine output warrants prompt assessment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source lists conventional tablet strengths but does not establish coating, scoring or modified-release properties. Confirm the product-specific tablet design, excipients and authorized age groups. Tablet and liquid dosing cannot be equated merely by package appearance.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Review symptom cause, age, hydration, gastrointestinal and renal risks, pregnancy and duplicate NSAID exposure. Confirm the exact locally authorized tablet information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specifications for each strength.
Approved labels/leaflets identifying release and administration instructions.
Strength-to-pack/SKU matrix and artwork.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: IbuprofenArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-221.
Professional enquiries
Request product-specific evidence for LP-221.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.